Kornimate/medical-research-clean huggingface dataset:
comparison of pulsed and thermal radiofrequency for trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: the goal of this clinical trial is to compare the effectiveness of pulsed radiofrequency (prf) with pulsed and thermal radiofrequency (prf + trf) in treating trigeminal neuralgia (tn) in adults. the main questions it aims to answer are: * does prf or prf + trf provide better pain relief for patients with trigeminal neuralgia? * what is the safety profile and complication rate of prf versus prf + trf? researchers will compare the effects of prf and prf + trf to see if thermal lesioning in addition to pulsed rf provides superior long-term pain relief and reduces the need for analgesic medication. participants will: * undergo either prf or prf + trf treatment targeting the trigeminal nerve. * be assessed for pain relief, functional status, and adverse events over a 3-month follow-up period.

this study is a randomized controlled trial designed to evaluate the efficacy and safety of pulsed radiofrequency (prf) versus pulsed and thermal radiofrequency (prf + trf) for treating trigeminal neuralgia (tn). trigeminal neuralgia is a debilitating chronic pain condition that affects the trigeminal nerve, causing intense facial pain. the study will enroll participants with tn, randomized into two groups: * group 1 (prf): patients will receive pulsed radiofrequency treatment with parameters set to standard levels for pain relief. * group 2 (prf + trf): patients will receive pulsed radiofrequency combined with thermal lesioning (60-70°c) to target the trigeminal nerve. both procedures will be performed under aseptic conditions with appropriate monitoring and anesthesia. the primary outcome will be pain reduction measured using the numeric rating scale (nrs) and visual analog scale (vas) over a 12-week period. secondary outcomes include changes in medication consumption assessed by the medication quantification scale iii (mqs iii) and the recording of procedure-related adverse events. participants will undergo follow-up assessments at week 1, week 4, and week 12 post-treatment.

Eligibility criteria:
inclusion criteria: * adults aged 18-60 years. * diagnosis of classical trigeminal neuralgia, as per the international classification of headache disorders criteria * patients experiencing unilateral, episodic facial pain for at least six months with a numeric rating scale (nrs) score greater than 6, despite medical treatment. * able to provide informed consent. * agree to follow the study procedures and attend follow-up visits. exclusion criteria: * patients with secondary trigeminal neuralgia (e.g., due to tumors, multiple sclerosis). * previous surgery or radiofrequency treatment for trigeminal neuralgia. * pregnant or breastfeeding women. * known allergies to anesthetics or other agents used in the procedure. * significant psychiatric disorders that may interfere with pain assessment or study participation. * coagulopathy or use of anticoagulants that contraindicate the procedure.

Keywords: trigeminal neuralgia pulsed radiofrequency thermal radiofrequency neuropathic pain facial pain radiofrequency ablation
hemodynamic effects of normobaric hypoxia during exercise in patients with pulmonary hypertension

Conditions: Hypertension, Pulmonary

Summary: to study hemodynamic effects of acute normobaric hypoxia during exercise in patients with pulmonary hypertension in a single-center randomized controlled trial.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature (appendix informed consent form) * ph class i (pah) or iv (cteph) diagnosed according to guidelines: mean pulmonary artery pressure \>20 mmhg, pulmonary vascular resistance ≥3 wood units, pulmonary arterial wedge pressure ≤15 mmhg during baseline measures at the diagnostic right-heart catheterization exclusion criteria: * resting partial pressure of oxygen \<8 kilopascal at zürich altitude on ambient air * exposure to an altitude \>1000 m for ≥3 nights during the last 2 weeks before the study * inability to follow the procedures of the study * patients who take nitrates * other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)

Keywords: hypoxia exercise hemodynamics
neuropsychological effects of hydrocortisone in patients with partial adrenal insufficiency

Conditions: Partial Corticotrope Insufficiency

Summary: the purpose of this study is to evaluate the efficacy of hydrocortisone replacement therapy in patients with partial cortisol deficiency after traumatic brain injury or subarachnoid hemorrhage on cognitive function.

this is a controlled, randomized, double-blind, placebo-controlled, crossover, interventional study. the benefit of replacement in partial corticotropic failure on brain function (cognition), especially in cases with borderline low cortisol levels after stimulation is unknown. moreover, since glucocorticoids might affect hgh secretion, the effect of hydrocortisone on hgh secretion reflected by igf-1 levels will be assessed. if igf-1 is below 2 sd at the end of the study, hgh secretion will additionally be determined by a ghrh-arginine-test. an improved cognition in tbi and sah patients with partial corticotropic insufficiency would give a new treatment option in this population which may lead to better quality of life and an enhanced rehabilitation process.

Eligibility criteria:
inclusion criteria: * adult patients (male and female) between 18 and 75 years * 1 -12 month after tbi or sah before prescreening * cortisol level 100-180 ng/ml after stimulation with acth * written informed consent by patient or a legally accepted representative exclusion criteria: * pregnancy and lactation period (during study treatment) * concomitant or previous high-dose therapy with glucocorticoids; previous treatment with glucocorticoids will be accepted, if it has been low dose (i.e. lower than the cushing threshold) and has been stopped at least 3 months before study participation * suspected or known hypersensitivity to hydrocortisone or any of its components * albumine less than 2,5 g/dl * suspected or known drug or alcohol abuse * planned treatment for thyroid dysfunction or a planned change in established thyroid treatment * any condition which in the opinion of the investigator makes the patient unsuitable for inclusion. * participation in another clinical trial with investigational new drugs * severe medical or psychiatric disease * change of dosage of any other drug which might influence the corticotrope axis or cognitive function (e.g. antidepressive treatment) during the last 3 weeks * oral contraceptives * severe disturbances in articulation, visual faculty or hearing * any elective surgery or medical treatment planned in the observation period * intensive care treatment

Keywords: neuropsychological effects of hydrocortisone replacement
efficacy and safety of insulin glargine/lixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: primary objective: * the purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio combination (frc) versus insulin glargine on glycemic control over 24 weeks, as evaluated by glycosylated hemoglobin (hba1c) reduction in type 2 diabetic participants treated with metformin. secondary objectives: * to compare insulin glargine/lixisenatide frc versus insulin glargine over 24 weeks on: * glycemic control in relation to a meal as evaluated by post-prandial plasma glucose and glucose excursions during a standardized meal test; * percentage of participants reaching hba1c \<7% or ≤6.5%; * 7-point self-monitored plasma glucose (smpg) profile; * body weight; * insulin glargine dose * fasting plasma glucose (fpg); * percentage of participants requiring rescue therapy during the 24-week open label treatment period; * to assess safety and tolerability of insulin glargine/lixisenatide frc.

approximately 27 weeks including a 24-week treatment period.

Eligibility criteria:
inclusion criteria: * participants with type 2 diabetes mellitus diagnosed for at least 1 year. * metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening. exclusion criteria: * age \< legal age of adulthood (18 years). * screening hba1c \ 10%. * screening fpg \>250 mg/dl (\>13.9 mmol/l). * pregnancy or lactation, women of childbearing potential with no effective contraceptive method. * type 1 diabetes mellitus. * treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening. * use of insulin within the last 6 months. * previous use of insulin, except for episode(s) of short-term treatment (≤15 consecutive days) due to intercurrent illness. * amylase and/or lipase \>3 times the upper limit of the normal laboratory range (uln) at screening. * calcitonin ≥20 pg/ml (5.9 pmol/l) at screening. * alanine transferase (alt) \>3 uln at screening. * history of unexplained pancreatitis, chronic pancreatitis, pancreatectomy. * personal or immediate family history of medullary thyroid cancer (mtc) or genetic conditions that predisposes to mtc (e.g. multiple endocrine neoplasia syndromes). * uncontrolled or inadequately controlled hypertension at the time of screening with a resting supine systolic or diastolic blood pressure \>180 mmhg or \>110 mmhg, respectively. * within the last 6 months prior to screening: history of heart failure requiring hospitalization, myocardial infarction, or stroke. planned coronary, carotid or peripheral artery revascularisation procedures. * body mass index (bmi) ≤20 or \>40 kg/m\^2. * any previous treatment with lixisenatide the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
study of the clinical utility of psma imaging in the evaluation of men with prostate cancer

Conditions: Prostate Cancer

Summary: in this study we aim to more precisely define the clinical utility of psma imaging across a range of clinical indications in men with prostate cancer. to accomplish this, we will make the 18f-dcfpyl pet/ct scan available to urologists, medical oncologists, and radiation oncologists at johns hopkins and survey physicians as to the indication for ordering the pet/ct and if a change in management occurred as the result of new information gained from the scan. we believe these data will prove critical for planning future studies aimed at evaluating the efficacy of this test for improving patient outcomes.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. willingness to signed informed consent 3. histologically confirmed adenocarcinoma of the prostate 4. psa measurement ≤60 days prior to study enrollment 5. completed radiographic evaluation with whole-body bone scan (99mtc-mdp or na18f) and cross-sectional imaging (ct or mri) of the abdomen and pelvis ≤60 days prior to study enrollment exclusion criteria: 1. administered a radioisotope within 5 physical half-lives prior to study enrollment 2. history of other malignancy diagnosed within the last 5 years (exceptions: low grade urothelial carcinoma of the bladder, squamous cell carcinoma or basal cell carcinoma of the skin).
acupuncture in treating nerve pain in patients with stage i, stage ii, or stage iii breast cancer who are receiving paclitaxel

Conditions: Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer

Summary: rationale: acupuncture may help relieve nerve pain caused by chemotherapy. purpose: this randomized clinical trial is studying how well acupuncture works in treating nerve pain in patients with stage i, stage ii, and stage iii breast cancer who are receiving paclitaxel.

primary objective: i. to explore the potential for the use of acupuncture to prevent a worsening of the nerve damage in patients (during treatment) due to paclitaxel as measured by a neuropathic pain symptom inventory. secondary objectives: i. evaluate the impact of acupuncture based on neurological assessment, quantitative sensory tests and nerve conduction tests. ii. evaluate the improvement observed when treating patients for peripheral neuropathy (post-chemotherapy) with acupuncture based on the same metrics. iii. to correlate objective measures of neuropathy (nerve conduction, quantitative sensory tests, neuropathy composite score, and blood cytokine levels) with the subjective questionnaire/quality of life measures. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients receive paclitaxel every 2 weeks for 4 courses as standard of care. patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4. arm ii: patients receive paclitaxel every 2 weeks for 4 courses as standard of care. patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.

Eligibility criteria:
inclusion * patients must have a history of histologically or cytologically confirmed stage i, ii, or iii breast cancer that have received 2 cycles of paclitaxel, and expected to receive paclitaxel for two more cycles, and are experiencing grade 1 peripheral neuropathy (ctcae criteria) * performance ecog 0-2 (karnofsky performance status \>= 60%) * life expectancy of greater than 6 months * ability to understand and the willingness to sign a written informed consent document exclusion * patients with radiologically confirmed stage iv breast cancer * patients who had acupuncture in the previous 8 weeks * change in use of any of the following drugs in the prior 4 weeks: opiates, antidepressants, or anxiolytics ("change" is defined as initiation or cessation of treatment, or change in prescribed dose or regimen) * patients with needle phobia * patients who experienced any peripheral neuropathy prior to chemotherapy * patients who have the potential for serious bleeding due to inherited diseases such as hemophilia * patients with diabetes

Keywords: male breast cancer neurotoxicity recurrent breast cancer
use of gadolinium in ct pulmonary angiography

Conditions: Pulmonary Embolism

Summary: the study will investigate patients with clinical suspicion for pulmonary embolism (pe) who have a contraindication to iodine based contrast. these patients normally get investigated with studies such as ultrasound and nuclear medicine studies but the fastest and preferred investigation is ct with contrast to look for filling defects in the pulmonary arteries. the investigators will assess whether gadolinium, which is currently used with mri can be used with ct as an alternative effective contrast in diagnosis or exclusion of pe. a new type of ct scanner, a dual energy scanner will be used to improve the visibility of gadolinium contrast on ct.

contrast enhancement with gadolinium will be evaluated to assess its efficacy for diagnosis and exclusion of pulmonary embolism in a patient who previously would not have been investigated with ctpa due to an underlying allergy to contrast or other contraindication. if this proves beneficial, it will allow such patients to be investigated successfully with ctpa

Eligibility criteria:
inclusion criteria: * patients suspected of having a pulmonary embolus * allergy to iodine based intravenous contrast exclusion criteria: * renal impairment * less than 20 years of age * non-english speaking * pregnancy * allergy to gadolinium

Keywords: pulmonary embolism contrast computed tomography gadolinium
feasibility of rct on the efficacy of the osteopathic consultation in computer users

Conditions: Trapezius Muscle Strain

Summary: this study investigates the feasibility of conducting a large scale randomized controlled trial (rct) to analyze the efficacy of the osteopathic consultation in reducing the intensity of pain and changing electromyographic activity in the musculature of the neck-shoulder region for the computer user's population.


Eligibility criteria:
inclusion criteria: * uses computer for over five hours daily, for over one year * reports non-specific pain over the neck-shoulder region exclusion criteria: * no neurologic signs or symptoms * no known pathology that could mask the reported pain * no knowledge or experience with osteopathy
megestrol in treating patients with liver cancer that cannot be removed by surgery

Conditions: Liver Cancer

Summary: rationale: estrogen can stimulate the growth of cancer cells. hormone therapy using megestrol may fight liver cancer by blocking the uptake of estrogen. it is not yet known if megestrol is an effective treatment for liver cancer. purpose: randomized phase iii trial to determine the effectiveness of megestrol in treating patients who have liver cancer that cannot be removed by surgery.

objectives: * compare the overall survival of patients with inoperable hepatocellular carcinoma treated with megestrol vs placebo. * compare the quality of life of patients treated with these drugs. outline: this is a randomized, double-blind, placebo-controlled, multicenter study. patients are stratified according to participating center. patients are randomized to 1 of 2 treatment arms. * arm i: patients receive oral megestrol twice daily for 1 year. * arm ii: patients receive an oral placebo twice daily for 1 year. quality of life is assessed at baseline and then monthly for 1 year. projected accrual: a minimum of 300 patients (200 for arm i and 100 for arm ii) will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of hepatocellular carcinoma (hcc) * histologically confirmed or * meets 2 of the following criteria: * radiological evidence of hcc on ct scan, mri, or ultrasound * serum alpha-fetoprotein level at least 400 µg/l * positive lipiodol retention * not amenable to surgery patient characteristics: age: * 20 to 100 performance status: * ecog 0-3 life expectancy: * not specified hematopoietic: * not specified hepatic: * bilirubin no greater than 5.8 mg/dl renal: * creatinine less than 1.7 mg/dl other: * not pregnant * no clinical encephalopathy * no other malignancy within the past 5 years prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemoembolization for hcc * no prior systemic chemotherapy for hcc endocrine therapy: * not specified radiotherapy: * not specified surgery: * see disease characteristics * no prior surgery for hcc other: * no prior percutaneous injection for hcc

Keywords: localized unresectable adult primary liver cancer advanced adult primary liver cancer adult primary hepatocellular carcinoma
pet and mri in the follow-up of neoadjuvant chemotherapy of breast cancer

Conditions: Breast Cancer

Summary: predict and follow thanks to imaging the response to neoadjuvant chemotherapy in locally advanced breast carcinoma. hypothesis : flt-(18f)pet will be a predictor superior to both fdg-(18f) pet and mri

pet/ct with fdg-(18f) and flt-(18f) and mri are performed at the initial staging, 3 times during sequential adjuvant chemotherapy and prior to surgery, aiming to find the most efficient modality to predict the response to neoadjuvant chemotherapy of the primary breast cancer and its possible lymph node metastases. post-surgical histology and a 6 month follow-up (to detect occult metastases) will constitute the standard of truth for determination and comparison of diagnostic performances.

Eligibility criteria:
inclusion criteria: * breast cancer scheduled for neoadjuvant chemotherapy followed by surgery exclusion criteria: * indicated chemotherapy without that a curative tumorectomies is foreseen(planned) * patient presenting an evolutionary infectious or inflammatory pathology, including an inflammatory breast cancer, being able to be source(spring) of false-positive results(profits) in tep-fdg * patient in the course of radiotherapy or of chemotherapy or operated at the level of the thorax in 4 weeks preceding the date foreseen(planned) by the examination tep (pose(installation) of implantable room(chamber) excludes) * diabetic waits * patient already includes in the other protocols of search(research) for nuclear medicine or for imaging using ionization radiations * patient not having given her lit(enlightened) assent * wait among which the surveillance tep or the mri during the chemotherapy will be impossible (that is by geographical or professional imperative, or if contraindication in the mri, ex: port(bearing) of a pacemaker, cochlear magnetic implants, metal foreign bodies cf protocol) * of less than 18 years old or pregnant patient. * breast cancer stage(stadium) iv * biopsy on the already realized mammary tumor, for the period(delay) lower than 15 j. * in case of alcoholic poisoning or of antecedents of reaction to the injection of ethanol: not inclusion to be discussed.

Keywords: comparison of imaging modalities predict the effectiveness of neoadjuvant chemotherapy
functional exercises with water intake in primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: dysmenorrhea and its associated symptoms are very common in women. in pakistan, almost 78% of women report primary dysmenorrhea. this will be a randomized controlled trial with two parallel groups. one group will be receiving functional exercises along with water intake and the other will be receiving no interventions.

mostly in the reproductive years of age women suffers from the pain of menstruation which is known as dysmenorrhea. in pakistan every other girl is silently suffers from this disease leading to the inefficiency and one of the main cause of school and work absenteeism. this novel study is designed to target the menstrual symptoms of women with functional exercises combine with optimal intake of water. the objective of this study is to determine the effects of functional exercises with water intake on menstrual symptoms and pain in primary dysmenorrhea. this is a randomized controlled study. before the study, all the participants will go through baseline evaluation, and then allocated to the groups. the exercise protocol consisting of the combination of exercises with regular intake of water (in bouts) will be informed to them. females fulfilling the criteria and willing to participate in exercise trial will be recruited in the study. outcome will be assessed at baseline and post treatment after 8th week.

Eligibility criteria:
inclusion criteria: * age group 15-35 * patients with pain at a severity level of 5 on nprs during menstruation. * primary dysmenorrhea diagnosis made on walidd score * patients having regular menstrual cycle exclusion criteria: * patients having some previous surgical history * patients diagnosed with secondary dysmenorrhea * abnormal cognition * involved in any regular physical activity for last 6 months

Keywords: functional exercises, water intake, menstrual pain, sleep